非囊性纖維化支氣管擴張症市場－全球產業規模、佔有率、趨勢、機會和預測，依治療方法、診斷、最終用途、地區和競爭格局分類，2020-2030年預測

2024年全球非囊性纖維化支氣管擴張症市場規模為37.1億美元，預計2030年將以5.30%的複合年成長率成長至50.6億美元。全球非囊性纖維化支氣管擴張症（NCFB）市場主要針對一種慢性肺部疾病，該疾病的特徵是氣道永久性擴張和增厚，與囊性纖維化不同，會導致粘液清除障礙和反覆呼吸道感染。該市場的主要促進因素是全球慢性呼吸系統疾病盛行率的不斷上升，以及診斷技術的顯著進步，例如高解析度CT掃描，這些進步有助於更早、更準確地識別疾病。

主要市場促進因素

非囊性纖維化支氣管擴張症 (NCFB) 在全球範圍內的日益流行，是推動市場發展的主要因素，直接提升了對診斷和治療資源的需求。診斷技術的進步、臨床醫生認知的提高以及對 NCFB 多種病因的深入了解，都進一步推動了這一趨勢。

主要市場挑戰

針對非囊性纖維化支氣管擴張症的特異性疾病改善療法數量有限，這極大限制了市場擴張。目前的治療方法主要著重於控制症狀和併發症，例如反覆感染，而不是解決疾病的根本進展。

主要市場趨勢

疾病修飾療法和生物療法的開發標誌著全球非囊性纖維化支氣管擴張症市場發生了關鍵性轉變，治療重點從症狀管理轉向直接改變疾病進展的干涉措施。這項轉變的重點包括旨在減輕發炎或破壞細菌定植的先進生物製劑和小分子藥物。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依治療方法（手術、物理治療、疫苗接種、氣道藥物治療、抗生素、其他）
  • 依診斷方法（CT掃描、支氣管鏡檢查、胸部X光檢查、肺功能檢查、痰液培養檢查、血液檢查、其他）
  • 依最終用途（醫院和診所、門診中心、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲非囊性纖維化支氣管擴張市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球非囊性纖維化支氣管擴張市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

第16章：策略建議

第17章調查會社について,免責事項

The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification.

Key Market Drivers

The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB's diverse etiologies. NCFB's chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase.

Key Market Challenges

The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.

Key Market Trends

The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:

• Surgery
• Physiotherapy
• Vaccination
• Airway pharmacotherapy
• Antibiotics
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:

• CT scan
• Bronchoscopy
• Chest X-ray
• Lung function
• Sputum culture test
• Blood tests
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By End use:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Surgery, Physiotherapy, Vaccination, Airway pharmacotherapy, Antibiotics, Others)
  • 5.2.2. By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others)
  • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End use
  • 6.3.2. Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End use
  • 6.3.3. Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End use

7. Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End use
  • 7.3.2. France Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End use
  • 7.3.3. United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End use
  • 7.3.4. Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By End use
  • 7.3.5. Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By End use

8. Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End use
  • 8.3.2. India Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End use
  • 8.3.3. Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End use
  • 8.3.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By End use
  • 8.3.5. Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By End use

9. Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End use
  • 9.3.2. UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End use
  • 9.3.3. South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End use

10. South America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Diagnosis
  • 10.2.3. By End use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By End use
  • 10.3.2. Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By End use
  • 10.3.3. Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Viatris Inc.
• 15.5. Teva Pharmaceutical Industries Ltd.
• 15.6. GSK plc
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Sun Pharmaceutical Industries Ltd.
• 15.9. Aurobindo Pharma Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer